H. Lundbeck A/S Newsletter
-
Lundbeck’s superagonist prompts 61.2% seizure reduction
04 Apr 2025 13:21 GMT
Lundbeck’s receptor superagonist designed to … of R&D at Lundbeck, said: “DEEs can be caused … multiple DEE types, and highlights Lundbeck’s expanding commitment to the … years.
Bexicaserin was acquired by Lundbeck as part of a $2 …
-
Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
04 Apr 2025 08:04 GMT
… month†, and sustained treatment response. Lundbeck remains focused on raising the … individual migraine experience
Details of Lundbeck presentations at AAN 2025:
Bexicaserin … of Investor Relations
MEEP@lundbeck.com
JSHR@lundbeck.com
+45 29 82 …
-
$16.43 Bn Alzheimer's Drugs Global Market Forecasts 2025-2033 Featuring Abbvie, AstraZeneca, Biogen, Eisai, Eli Lilly and Co, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck, Novartis, Ono, Pfizer, Teva - ResearchAndMarkets.com
14 Mar 2025 13:14 GMT
… .
Eli Lilly and Company
H. Lundbeck A/S
F. Hoffmann …
-
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
14 Mar 2025 11:42 GMT
… ) has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic Rxulti … and the secondary on efficacy.
Lundbeck research and development head and … partnership and licence agreement between Lundbeck and Otsuka Pharmaceutical Europe.
Otsuka …
-
Lundbeck’s MSA Treatment Receives Orphan Drug Designation in Japan
11 Mar 2025 19:02 GMT
… Orphan Drug Designation (ODD) to Lundbeck’s investigational drug, amlenetug, a … Atrophy (MSA).
H. Lundbeck A/S (Lundbeck) announced that amlenetug has … of Research & Development at Lundbeck.
Lundbeck has recently initiated, MASCOT, a …
-
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
11 Mar 2025 14:49 GMT
Lundbeck has gained orphan drug … and Danish biotechnology firm Genmab.
Lundbeck has commenced a randomised, … infusion every four weeks.
Lundbeck research and development head and … neuro-rare disease sector, Lundbeck completed the acquisition of all …
-
Japan grants Orphan Drug Designation to Lundbeck's potential treatment for Multiple System Atrophy
11 Mar 2025 09:25 GMT
… Orphan Drug Designation to Lundbeck's potential treatment … 11, 2025 | Tuesday | News
Lundbeck has recently initiated MASCOT trial … Drug Designation (ODD) to Lundbeck's investigational drug, … is being developed by Lundbeck under a joint research …
-
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy
11 Mar 2025 08:59 GMT
… of research & development at Lundbeck.
Lundbeck has recently initiated, MASCOT, … is being developed by Lundbeck under a joint research and … licensing agreement between Lundbeck and Genmab A… slow its progression.
H. Lundbeck A/S is a …
-
Lundbeck’s Amlenetug for MSA Receives FDA Fast Track Designation
14 Feb 2025 14:04 GMT
… Fast Track Designation to Lundbeck’s investigational drug, amlenetug … Multiple System Atrophy (MSA). Lundbeck has recently initiated MASCOT, … .
With this designation, Lundbeck will benefit from all FDA … & Development at Lundbeck.
Amlenetug has also been …
-
Lundbeck gains FDA fast track designation for MSA therapy amlenetug
12 Feb 2025 16:09 GMT
…
The designation will provide Lundbeck with the possibility of … Phase II AMULET trial.
Lundbeck research and development head … and licensing agreement between Lundbeck and Genmab, the drug … neuro-rare disease sector, Lundbeck completed the acquisition of …
About
© 1995-2025